apg-1252
Small moleculeexperimental
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 12, 2017 (NCT03080311)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Endometrial Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Neoplasms · Phase 1
- Neuroendocrine Tumors · Phase 1
- Ovarian Neoplasms · Phase 1
- Primary Myelofibrosis · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Uterine Neoplasms · Phase 1
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(S(C)(=O)=O)c(-c2cc(F)cc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(C(=O)OCCCP(=O)(O)O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C(C)C- Mol. weight
- 1281.87 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802151 ↗
Also known as
- apg-1252
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05691504 | Phase 1 | Sep 14, 2023 | Harvard University, National Cancer Institute (NCI) |
| NCT05186012 | Phase 1/Phase 2 (Phase 2) | Jun 20, 2022 | Ascentage Pharma Group Inc. |
| NCT04893759 | Phase 1 | Nov 30, 2021 | Ascentage Pharma Group Inc., Fudan University, Sun Yat-Sen University |
| NCT04354727 | Phase 1/Phase 2 (Phase 2) | May 30, 2020 | Ascentage Pharma Group Inc. |
| NCT04210037 | Phase 1/Phase 2 (Phase 2) | Jan 15, 2020 | Ascentage Pharma Group Inc. |
| NCT04001777 | Phase 1 | Jul 31, 2019 | Ascentage Pharma Group Inc., Sun Yat-Sen University |
| NCT03387332 | Phase 1 | Dec 1, 2017 | Ascentage Pharma Group Inc. |
| NCT03080311 | Phase 1 | Feb 12, 2017 | Ascentage Pharma Group Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascentage Pharma Group Inc. | For profit | 7 | 7 | 2 | 2017 |
| Sun Yat-Sen University | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1